Processa Pharmaceuticals (PCSA) Retained Earnings (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Retained Earnings came in at -$104.2 million in Q1 2026, down 15.66% YoY from -$123.5 million in Q1 2025, and down 3.35% on a QoQ basis from -$100.8 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Retained Earnings (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Retained Earnings data on file, last reported at -$104.2 million in Q1 2026.
- Quarterly Retained Earnings fell 15.66% year-over-year to -$104.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$104.2 million (down 15.66% YoY) and the FY2025 annual result came in at -$100.8 million, down 15.55% from the prior year.
- Retained Earnings eased to -$104.2 million in Q1 2026, from -$100.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$40.1 million in Q1 2022 to a low of -$104.2 million in Q1 2026.
- A 5-year average of -$76.8 million and a median of -$78.1 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 74.48% — and 2024, when it fell 14.34%.
- Tracing PCSA's Retained Earnings over 5 years: stood at -$64.2 million in 2022, then slipped by 17.31% to -$75.4 million in 2023, then slipped by 15.72% to -$87.2 million in 2024, then slipped by 15.55% to -$100.8 million in 2025, then retreated by 3.35% to -$104.2 million in 2026.
- The last three Retained Earnings figures came in at -$104.2 million (Q1 2026), -$100.8 million (Q4 2025), and -$97.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 4.38 Bn |
| 10 | Processa Pharmaceuticals | 5.72 Mn | 5.72 Mn | - | -107.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.16 Mn |
| Dec 31, 2025 | -100.78 Mn |
| Sep 30, 2025 | -97.40 Mn |
| Jun 30, 2025 | -94.00 Mn |
| Mar 31, 2025 | -90.05 Mn |
| Dec 31, 2024 | -87.22 Mn |
| Sep 30, 2024 | -84.50 Mn |
| Jun 30, 2024 | -81.11 Mn |
| Mar 31, 2024 | -78.10 Mn |
| Dec 31, 2023 | -75.37 Mn |
| Sep 30, 2023 | -72.96 Mn |
| Jun 30, 2023 | -70.90 Mn |
| Mar 31, 2023 | -68.30 Mn |
| Dec 31, 2022 | -64.25 Mn |
| Sep 30, 2022 | -51.20 Mn |
| Jun 30, 2022 | -45.20 Mn |
| Mar 31, 2022 | -40.05 Mn |
| Dec 31, 2021 | -36.82 Mn |
| Sep 30, 2021 | -33.64 Mn |
| Jun 30, 2021 | -30.70 Mn |